Basel Medical Group Ltd
Basel Medical Group Ltd is a Singapore-based healthcare services provider focused on specialist medical care across orthopedics, trauma, sports medicine, neurosurgery, and general practice. The company delivers consultations, medical diagnosis, and both surgical and non-surgical treatments, with services that include joint replacement, spine care, foot and ankle procedures, minimally invasive orthopedic care, physiotherapy, and rehabilitation. It also offers health screening, mental health, and women’s health services, supporting a broader patient-care pathway within its clinics and medical centers. Basel Medical Group Ltd operates within the healthcare services market, where it serves patients seeking integrated treatment across multiple disciplines and procedures. Its current business model centers on clinical care delivery and specialist expertise in private healthcare settings in Singapore.
$3.93
+$0.02 (+0.51%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-19.22% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 12.6%, still solid. Margins contracted 41.1pp, which offsets some of the top-line progress.
Free cash flow declined 245% versus the prior year, cash generation momentum has weakened. ROIC dropped from 15.41% to -15.37%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
SGD 11M
▲ +12.6% YoY
Net Income (TTM)
-SGD 11M
▼ -613.1% YoY
Op. Margin
-19.22%
▼ -41.1pp YoY
ROIC
-15.37%
▼ -30.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-SGD 4M
▼ -244.6% YoY
Op. Cash Flow (TTM)
-SGD 3M
▼ -226.7% YoY
Net Debt
SGD 2M
Cash & Equiv.
SGD 3M
3Y CAGR: +11.6%
Continue Research
Is Basel Medical Group (BMGL) overvalued?
Basel Medical Group (BMGL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Basel Medical Group scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Basel Medical Group a high-quality business?+
Basel Medical Group scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -19.2% operating margin and a -15.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Basel Medical Group a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh BMGL's valuation and scores 15/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Care Facilities
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.